Natixis Advisors LLC Acquires 82,894 Shares of Hologic, Inc. $HOLX

Key Points

• Natixis Advisors LLC increased its stake in Hologic by 23.4%, buying 82,894 shares to own 437,338 shares (about 0.20% of the company) worth roughly $29.52 million.
• Hologic missed quarterly expectations, reporting $1.04 EPS vs. $1.09 expected and $1.05 billion in revenue vs. $1.07 billion expected, though revenue was up 2.5% year‑over‑year.
• Analysts hold a consensus "Hold" rating with a $78.42 target price (2 buys, 13 holds); the stock has a $16.86 billion market cap and a PE of 31.48, trading near its 52‑week high of $75.75.

Natixis Advisors LLC increased its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 23.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 437,338 shares of the medical equipment provider's stock after purchasing an additional 82,894 shares during the period. Natixis Advisors LLC owned approximately 0.20% of Hologic worth $29,516,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Winnow Wealth LLC purchased a new position in Hologic in the 3rd quarter worth approximately $26,000. Root Financial Partners LLC purchased a new stake in shares of Hologic during the 3rd quarter valued at $27,000. SJS Investment Consulting Inc. lifted its holdings in shares of Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider's stock worth $32,000 after acquiring an additional 362 shares during the last quarter. Loomis Sayles & Co. L P bought a new stake in shares of Hologic during the 2nd quarter worth $33,000. Finally, Smartleaf Asset Management LLC grew its position in Hologic by 168.5% in the third quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider's stock worth $33,000 after acquiring an additional 310 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $75.54 on Wednesday. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. The stock has a market cap of $16.86 billion, a PE ratio of 31.48, a PEG ratio of 2.25 and a beta of 0.73. The company's fifty day moving average is $75.08 and its 200 day moving average is $72.55. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $75.75.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The business had revenue of $1.05 billion for the quarter, compared to analysts' expectations of $1.07 billion. During the same quarter in the previous year, the company earned $0.87 earnings per share. The business's quarterly revenue was up 2.5% on a year-over-year basis. Research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on HOLX. Argus cut Hologic from a "buy" rating to a "hold" rating in a research note on Monday, January 12th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Hologic in a research note on Wednesday, January 28th. Morgan Stanley increased their price objective on Hologic from $69.00 to $76.00 and gave the company an "equal weight" rating in a research report on Tuesday, November 11th. BNP Paribas Exane cut Hologic from a "strong-buy" rating to a "hold" rating and set a $79.00 price objective on the stock. in a report on Friday, November 21st. Finally, Evercore downgraded Hologic from an "outperform" rating to an "in-line" rating and dropped their target price for the stock from $79.00 to $78.00 in a research report on Monday, January 5th. Two investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat, Hologic presently has a consensus rating of "Hold" and a consensus target price of $78.42.

About Hologic

Hologic, Inc NASDAQ: HOLX is a global medical technology company specializing in women's health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.